Page last updated: 2024-11-07

metaraminol and Malignant Carcinoid Syndrome

metaraminol has been researched along with Malignant Carcinoid Syndrome in 1 studies

Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.
metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.

Malignant Carcinoid Syndrome: A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
von Studnitz, W1
Waldenström, J1

Other Studies

1 other study available for metaraminol and Malignant Carcinoid Syndrome

ArticleYear
[Pharmacological and therapeutic studies (p-chlorphenylalanin) on carcinoid syndrome in 11 cases].
    Klinische Wochenschrift, 1971, Jul-01, Volume: 49, Issue:13

    Topics: 5-Hydroxytryptophan; Aged; Blood Pressure; Bradykinin; Epinephrine; Female; Fenclonine; Humans; Hydr

1971